ClinicalTrials.gg
CompletedNCT04776772Updated Mar 2, 2021

Health Parameters in Soccer Players and Sedentary Individuals After Consuming a Synbiotic

An interventional study of Synbiotic complement and Placebo in Athlete and Sedentary Behavior, sponsored by Catholic University of Murcia. Completed at 1 site in Spain. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-02.

Sponsored by Catholic University of Murcia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled May 2019, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Sedentary Behavior with a site in Spain — 21 open to participants now, 30 under way, none of them phase 3. Sedentary Behavior · Spain.

Enrollment
46th of 48
27 · median 120
Started
2019
with 3 others
No phase
48 of 64
13 open now
Registered
15th of 64
by date

Among the 64 studies in Sedentary Behavior with a site in Spain, this one is the 46th largest by enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2019, is one of 48 with no phase, and was the 15th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

21 of the 64 studies in Sedentary Behavior with a site in Spain are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 30 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Sedentary Behavior with a site in Spain, or all of them as a file.
02

Study summary

The main objective of this research was to carry out an experimental study, triple blind, on the possible immunophysiological effects of a nutritional supplement (Synbiotic, Gasteel Plus®, Heel España S.A.U.), containing a mixture of probiotic strains, such as Bifidobacterium lactis CBP-001010, Lactobacillus rhamnosus CNCM I-4036, Bifidobacterium longum ES1, as well as prebi-otic fructooligosaccharides, in both professional athletes and sedentary people. The effects on some inflammatory/immune (IL-1β, IL-10, and immunoglobulin A) and stress (epinephrine, nore-pinephrine, dopamine, serotonin, CRH, ACTH, and cortisol) biomarkers were evaluated, determined by flow cytometer and ELISA. The effects on metabolic profile and physical activity, as well as on various parameters that could affect physical and mental health, were also evaluated via the use of accelerometry and validated questionnaires.

Read the detailed description

This investigation was a triple blinded, randomized, placebo-controlled pilot study designed to identify the possible differing effects of the synbiotic Gasteel Plus® supplementation.

The participants were professional soccer players of the Second Division B of the Spanish League and sedentary students of the same sex and age range. Both study groups were randomly divided into two groups: a control group administered with placebo, and an experimental group administered with the synbiotic. Each participant was evaluated at baseline, as well as after the intervention which lasted one month. Only in the athletes group did the synbiotic intervention clearly improve objective physical activ-ity and sleep quality, as well as perceived general health, stress, and anxiety levels.

03

Conditions studied

  • Athlete
  • Sedentary Behavior

Keywords

  • anxiety
  • immunity
  • inflammation
  • prebiotic
  • probiotic
  • sedentarism
  • soccer
  • stress
  • synbiotic
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sedentary individuals: students with low levels of physical activity (≤ 150 minutes/week),
  • Athletes: semi professional soccer players

Exclusion criteria

Exclusion Criteria:

  • Participants were prohibited from consuming probiotics, prebiotics or fermented products (yogurt or other foods)
  • Presenting injury or illness
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Placebo comparator
    Soccer player placebo

    Soccer player consuming placebo sticks filled with 300 mg excipient of maltodextrin

    Dietary Supplement: Placebo

  • Experimental
    Soccer player synbiotic

    Soccer players consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic

    Dietary Supplement: Synbiotic complement

  • Placebo comparator
    Sedentary individuals placebo

    Sedentary individuals consuming placebo sticks filled with 300 mg excipient of maltodextrin

    Dietary Supplement: Placebo

  • Experimental
    Sedentary individuals synbiotic

    Sedentary individuals consuming a mixture of probiotic strains: Bifidobacterium lactis CBP-001010, Lactobacillus rhamno-sus CNCM I-4036, Bifidobacterium longum ES1 and fructooligosaccharides (200 mg) as a prebiotic

    Dietary Supplement: Synbiotic complement

Interventions

  • Dietary supplementSynbiotic complement

    On two separate days, the "baseline-tests" and "final-tests" were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the "final-test" and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic).

  • Dietary supplementPlacebo

    On two separate days, the "baseline-tests" and "final-tests" were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the "final-test" and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo).

06

What researchers measure

Primary outcomes

  1. Objective determination of levels of physical activity, sedentary lifestyle and sleep quality: accelerometry

    Participants wore the accelerometer held with an elastic band on the non-dominant wrist for 7 consecutive days and without interruption, except for those times of the day in which the correct operation of the device could be compromised (showers or any activity related to wa-ter). Subsequently, the files generated by the accelerometer were analyzed through a specific software called Actilife 6 (Actigraph, Pensacola, USA).

    Time frame: During 7 days before the ingestion of the synbiotic or placebo

  2. Objective determination of levels of physical activity, sedentary lifestyle and sleep quality: accelerometry

    Participants wore the accelerometer held with an elastic band on the non-dominant wrist for 7 consecutive days and without interruption, except for those times of the day in which the correct operation of the device could be compromised (showers or any activity related to wa-ter). Subsequently, the files generated by the accelerometer were analyzed through a specific software called Actilife 6 (Actigraph, Pensacola, USA).

    Time frame: During 7 days after the ingestion of the synbiotic or placebo

  3. Questionnarie about general health.

    SF-36 Questionnaire: Scale from 0 to 100. Higher scores mean a better outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  4. Questionnarie about general health.

    SF-36 Questionnaire: Scale from 0 to 100. Higher scores mean a better outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  5. Questionnarie about anxiety levels (moment)

    The State Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  6. Questionnarie about anxiety levels (moment)

    The State Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  7. Questionnarie about anxiety levels (personality)

    The Trait Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  8. Questionnarie about anxiety levels (personality)

    The Trait Anxiety Inventory (STAI): Scale from 0 to 60. Higher scores mean a worse outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  9. Questionnarie about sleep quality

    Healthy Lifestyle and Personal Control Questionnaire: Scale from -1 to 10. Higher scores mean a better outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  10. Questionnarie about sleep quality

    Healthy Lifestyle and Personal Control Questionnaire: Scale from -1 to 10. Higher scores mean a better outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  11. Questionnarie about perceived stress

    The Perceived Stress Scale: Scale from 0 to 56. Higher scores mean a worse outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  12. Questionnarie about perceived stress

    The Perceived Stress Scale: Scale from 0 to 56. Higher scores mean a worse outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  13. Questionnarie about perceived fatigue

    Brief Fatigue Inventory: Scale from 0 to 40. Higher scores mean a worse outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  14. Questionnarie about perceived fatigue

    Brief Fatigue Inventory: Scale from 0 to 40. Higher scores mean a worse outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  15. Questionnarie about perceived depression

    Beck´s Depression Inventory: Scale from 0 to 63. Higher scores mean a worse outcome.

    Time frame: One day before the ingestion of the synbiotic or placebo

  16. Questionnarie about perceived depression

    Beck´s Depression Inventory: Scale from 0 to 63. Higher scores mean a worse outcome.

    Time frame: One day after the ingestion of the synbiotic or placebo

  17. Determination of the pro-inflammatory cytokine IL-1β (Blood sampling)

    Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  18. Determination of the pro-inflammatory cytokine IL-1β (Blood sampling)

    Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  19. Determination of the anti-inflammatory cytokine IL-10 (Blood sampling)

    Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  20. Determination of the anti-inflammatory cytokine IL-10 (Blood sampling)

    Using the LuminexTM 200 System instrument (Luminex Corporation, Texas, USA) using the ProcartaPlex TM Multiplex Immunoassay for analysis. Measured in pg/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  21. Determination of the stress hormones Cortisol (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The DetectX Cortisol Immunoassay Kit. Measured in µg/dl.

    Time frame: One day before the ingestion of the synbiotic or placebo

  22. Determination of the stress hormones Cortisol (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The DetectX Cortisol Immunoassay Kit. Measured in µg/dl.

    Time frame: One day after the ingestion of the synbiotic or placebo

  23. Determination of the adrenocorticotropic hormone (ACTH) (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human ACTH (Adrenocorticotropic Hormone) ELISA Kit (Elabscience, USA). Measured in pg/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  24. Determination of the adrenocorticotropic hormone (ACTH) (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human ACTH (Adrenocorticotropic Hormone) ELISA Kit (Elabscience, USA). Measured in pg/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  25. Determination of the corticotropin-releasing hormone (CRH) (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human Corticotropin Releasing Hormone (CRH) RD-CRH-Hu (Kelowna, BC, V1W 4V3, Canada) Measured in pg/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  26. Determination of the corticotropin-releasing hormone (CRH) (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Human Corticotropin Releasing Hormone (CRH) RD-CRH-Hu (Kelowna, BC, V1W 4V3, Canada) Measured in pg/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  27. Determination of the stress hormones serotonin (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General 5-Hydroxytryptamine (5-HT) RD-5-HT-Ge. Measured in ng/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  28. Determination of the stress hormones serotonin (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General 5-Hydroxytryptamine (5-HT) RD-5-HT-Ge. Measured in ng/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  29. Determination of the catecholamine dopamine (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Dopamine Research Immunoassay Measured in ng/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  30. Determination of the catecholamine dopamine (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The Dopamine Research Immunoassay Measured in ng/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  31. Determination of the catecholamine epinephrine (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Epinephrine (EPI) RD-EPI-Ge-96T. Measured in pg/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  32. Determination of the catecholamine epinephrine (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Epinephrine (EPI) RD-EPI-Ge-96T. Measured in pg/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  33. Determination of the catecholamine norepinephrine (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Noradrenaline (NE) RD-NE-Ge-96T. Measured in pg/ml.

    Time frame: One day before the ingestion of the synbiotic or placebo

  34. Determination of the catecholamine norepinephrine (Blood sampling)

    Analyzed by competitive inhibition enzyme immunoassays (ELISA), using The General Noradrenaline (NE) RD-NE-Ge-96T. Measured in pg/ml.

    Time frame: One day after the ingestion of the synbiotic or placebo

  35. Determination of the immunoglobulin A (Saliva sampling)

    Analyzed by indirect enzyme immunoassay kit through the Salivary Secretory IgA Kit (Salimetrics LLC, USA). The procedures followed the instructions of the manufacturers, and the findings were measured using an ELISA auto analyzer to quantify color intensity (Sunrise, Tecan, Männendorf, Switzerland). Measured in µg/ml

    Time frame: One day before the ingestion of the synbiotic or placebo

  36. Determination of the immunoglobulin A (Saliva sampling)

    Analyzed by indirect enzyme immunoassay kit through the Salivary Secretory IgA Kit (Salimetrics LLC, USA). The procedures followed the instructions of the manufacturers, and the findings were measured using an ELISA auto analyzer to quantify color intensity (Sunrise, Tecan, Männendorf, Switzerland). Measured in µg/ml

    Time frame: One day after the ingestion of the synbiotic or placebo

  37. Determination of glucose levels (metabolic profile)

    The determinations for obtaining the glycemic profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl

    Time frame: One day before the ingestion of the synbiotic or placebo

  38. Determination of glucose levels (metabolic profile)

    The determinations for obtaining the glycemic profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl

    Time frame: One day after the ingestion of the synbiotic or placebo

  39. Determination of total cholesterol levels (metabolic profile)

    The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl

    Time frame: One day before the ingestion of the synbiotic or placebo

  40. Determination of total cholesterol levels (metabolic profile)

    The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl

    Time frame: One day after the ingestion of the synbiotic or placebo

  41. Determination of the triglycerides levels (metabolic profile)

    The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl

    Time frame: One day before the ingestion of the synbiotic or placebo

  42. Determination of the triglycerides levels (metabolic profile)

    The determinations for obtaining the lipid profile were carried out through standard techniques with the automatic analyzer of clinical chemistry BA 400 (BioSystems) in the SYNLAB laboratories (Diagnosticos Globales S.A.U., Badajoz, Spain). Measured in mg/dl

    Time frame: One day after the ingestion of the synbiotic or placebo

07

Study locations

1 site
  • Catholic University of Murcia
    Murcia, 30107, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The raw data supporting the conclusions of this intervention will be made available by the investigators, without undue reservation, to any qualified researcher

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The data will be always available upon reasonable request

Access criteria: The data that support the findings of this study are available via email from the corresponding author upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jun 2019, 1 month.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 1 month is below that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Mar 2, 2021
StartActual
May 15, 2019
Primary completionActual
Jun 16, 2019
CompletionActual
Jun 30, 2019
Last update
Mar 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04776772
Lead sponsor
Catholic University of Murcia
Responsible party
Carmen Daniela Quero Calero (Professor, principal investigator, Catholic University of Murcia) — Principal investigator
First posted
Mar 2, 2021
Start date
May 15, 2019
Primary completion
Jun 16, 2019
Completion
Jun 30, 2019
Last update
Mar 2, 2021

Study contacts

Carmen Quero, PhD
principal investigator · Catholic University of Murcia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion